It remains uncertain how long Gilead Sciences, Inc.’s COVID-19 antiviral Veklury (remdesivir) will be a significant source of sales as infection rates fall in the US, vaccination rates increase and more drugs become available, but a new cache of real-world data showing a mortality benefit could help the drug retain its role as a standard of care.
Gilead is presenting data at the World Microbe Forum, running 20-24 June, from three analyses of real-world datasets that it...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?